NEWS

Gains in tRNAslation: It’s time for investors to realize the potential of European RNA technologies

November 2, 2020

Dr. Gur Roshwalb, aMoon Managing Director, discusses how investing in new innovative RNA technologies can lead to rapid value creation, and why Europe is a fertile ground to hunt for them.

Read More

Remote electric neuromodulation device approval extended to treatment of chronic migraine

October 27, 2020

The Food and Drug Administration (FDA) has expanded the approval of Nerivio® (Theranica) to include acute treatment of migraine with or without aura in patients aged 18 years and older with chronic migraine. Previously, the device had only been approved in those with episodic migraine.

Read More

Combining machine learning tools for medical imaging with genetic sequencing nets Sophia Genetics $110M

October 1, 2020

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics added another $110 million to its coffers in a series F financing led by aMoon and Hitachi Ventures.

Read More

Venture capitalists find more to Israel than Zionism

September 30, 2020

Not all olim arrive in Israel to serve in the IDF or go to university. In the case of two aMoon executives, coming to Israel was a way to advance their careers in venture capital health investments while also reaching the goal of living in the Jewish state.

Read More

Alexa, do I have COVID-19?

September 30, 2020

In March, as the staggering scope of the pandemic started to become clear, officials around the world began enlisting the public to join in the fight. In Israel, the defense ministry and a start-up company called Vocalis Health asked people to donate their voices.

Read More

Adicet Announces Completion of Merger with resTORbio

September 15, 2020

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the completion of its previously announced merger with resTORbio, Inc

Read More

Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing

September 15, 2020

Seer, Inc., an aMoon2 portfolio company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced that it has spun out and completed the initial financing of $55M for a newly formed healthcare company, PrognomIQ, Inc.

Read More

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

September 10, 2020

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the completion of a £23 million ($30 million) Series A equity financing led by aMoon, Israel’s largest healthtech and life sciences venture fund.

Read More

MOBILion Closes $35M Series B Financing Round

August 17, 2020

aMoon leads round to expand product portfolio and advance commercial efforts for MOBILion’s SLIM technology for biotherapeutics characterization and novel biomarker discovery

Read More

Roche invests millions in Israel’s health tech sector

August 11, 2020

has entered into a partnership agreement with aMoon, an Israeli venture capital company focused on health technology and science. The “StarFinder Lab” collaboration is aiming to help young startups develop innovative diagnostic tools to tackle global health care challenges.

Read More

CartiHeal raises $18.3m to support PMA trial of Agili-C implant

May 8, 2017

CartiHeal said today it raised $18.3 million in a new round of financing to support an FDA IDE-approved clinical trial of its Agili-C implant for use in repairing cartilage and osteochondral defects.

Read More

Israeli Universal Flu Vaccine Maker Receives $2.8 Million Investment

January 4, 2017

Israeli billionaire Marius Nacht is banking on Israeli bio-tech with a $2.8 million investment into BiondVax Pharmaceuticals, a clinical phase company developing a universal flu vaccine.

Read More